Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Maxcyte (MXCT) Assets Average (2021 - 2025)

Historic Assets Average for Maxcyte (MXCT) over the last 5 years, with Q3 2025 value amounting to $216.6 million.

  • Maxcyte's Assets Average fell 1337.35% to $216.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $216.6 million, marking a year-over-year decrease of 1337.35%. This contributed to the annual value of $253.9 million for FY2024, which is 850.26% down from last year.
  • Per Maxcyte's latest filing, its Assets Average stood at $216.6 million for Q3 2025, which was down 1337.35% from $224.9 million recorded in Q2 2025.
  • Over the past 5 years, Maxcyte's Assets Average peaked at $290.4 million during Q2 2022, and registered a low of $185.4 million during Q3 2021.
  • For the 5-year period, Maxcyte's Assets Average averaged around $259.1 million, with its median value being $267.5 million (2023).
  • Per our database at Business Quant, Maxcyte's Assets Average skyrocketed by 5537.51% in 2022 and then crashed by 1337.35% in 2025.
  • Over the past 5 years, Maxcyte's Assets Average (Quarter) stood at $280.9 million in 2021, then grew by 2.0% to $286.5 million in 2022, then dropped by 6.64% to $267.5 million in 2023, then decreased by 8.77% to $244.0 million in 2024, then fell by 11.24% to $216.6 million in 2025.
  • Its Assets Average was $216.6 million in Q3 2025, compared to $224.9 million in Q2 2025 and $234.7 million in Q1 2025.